Search hospitals > Ohio > Columbus
The Mark H Zangmeister Center
Claim this profileColumbus, Ohio 43219
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Ovarian Cancer
Conducts research for Cancer
275 reported clinical trials
7 medical researchers
Summary
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cancer and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 387 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
126 reported clinical trials
208 drugs studied
Jeanna L KnobleZangmeister Cancer Center3 years of reported clinical research
Studies Breast Cancer
Studies Pancreatic Cancer
3 reported clinical trials
11 drugs studied
Sameh Mikhail, MDZangmeister Cancer Center5 years of reported clinical research
Studies Colorectal Cancer
Studies Ovarian Cancer
2 reported clinical trials
3 drugs studied
Emily WhitmanZangmeister Cancer Center5 years of reported clinical research
Studies Fallopian Tube Cancer
Studies Ovarian Cancer
2 reported clinical trials
4 drugs studied
Clinical Trials running at The Mark H Zangmeister Center
Lung Cancer
Breast Cancer
Cancer
Bladder Cancer
Ovarian Cancer
Melanoma
Pancreatic Cancer
Colorectal Cancer
Cutaneous Melanoma
Bladder Carcinoma
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at The Mark H Zangmeister Center?
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cancer and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 387 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.